GET DAILY SIGNALSKyntra Bio (KYNB) Analyst Targets Point to +850% Upside Potential
Key Takeaways
- The $37 central target is the arithmetic mean of five verified analyst price targets for Kyntra Bio, which range from $30 to $43.
- The stock last traded near $3.90, so reaching $37 implies roughly 850% upside — a very large move.
- The bull case rests on the FG-3246 oncology program, a cash position far above the company's market value, and mostly Buy/Outperform ratings.
- Key risks include a recent decline of roughly half that predates the latest targets, clinical-development risk, and a very small market capitalization of about $16 million.
- For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
- Discover Trending AI Robots to follow AI-driven trading signals across thousands of stocks and ETFs.
Analyst Price Targets and Consensus View
Kyntra Bio, Inc. (KYNB) is a San Francisco-based biopharmaceutical company — formerly FibroGen — developing oncology and rare-disease therapies. Its analyst coverage is thin but generally constructive. Five verifiable price targets were reviewed: Oppenheimer at $35 (Outperform, initiated in mid-2026 and maintained in August), Rodman & Renshaw at $30 (Buy, June 2026), H.C. Wainwright at $43 (Buy, reiterated October 2026), Lake Street at $41 (Buy, September 2026), and Maxim at $35 (Buy, October 2026). The arithmetic mean of these five targets is $36.80, rounded to $37 for the central target, with a low-to-high range of $30 to $43.
Views differ mainly on how much credit to assign to FG-3246, a CD46-targeting antibody-drug conjugate (ADC) in Phase II for metastatic castration-resistant prostate cancer (mCRPC), and on the value of the company's cash. Most ratings are Buy or Outperform, with one Hold among recent reviews. This is a small sample, and no single figure should be treated as a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The stock last traded near $3.90, within a 52-week range of $3.60 to $11.19. Reaching $37 would require a gain of roughly 850% from current levels — a very large move even by the standards of speculative biotechnology.
It is important to note that most targets were set when the stock traded around $7 to $8, before a decline of roughly half over recent months. The gap between the current price and the targets therefore reflects a falling share price more than a rising forecast, and several price targets may not yet have caught up with the slide. A path toward $37 would likely depend on positive clinical data that materially re-rates the company.
What Could Support a Move Toward the Target
- Cash position: Kyntra Bio reported roughly $91 million in cash, far above its market capitalization, giving it a negative enterprise value and a meaningful operating runway.
- Pipeline catalysts: FG-3246 and the companion CD46-targeted PET biomarker FG-3180 address a persistent unmet need in mCRPC, while roxadustat (EVRENZO) is already approved outside the U.S. for anemia in chronic kidney disease.
- Analyst posture: initiations and reiterations of Buy and Outperform ratings through late 2026 signal continued institutional interest.
What Could Prevent the Target From Being Reached
- Clinical risk: a failed or inconclusive Phase II readout for FG-3246 could invalidate the core bull thesis.
- Micro-cap dynamics: limited trading liquidity and a small float can produce sharp, disproportionate price swings.
- Stale targets: several price targets predate the recent decline and may overstate near-term fair value.
- Dilution: as a development-stage company, future capital raises could pressure the share count.
Technical Levels and Market Structure
The 52-week low of $3.60 sits just below the current price and is the nearest support level; a decisive break below it would leave the stock in record territory. On the upside, the $5 and $10 round numbers, along with the prior high near $11.19, mark the most visible resistance zones before any move toward the $30s could be contemplated. From what I see, these levels provide useful reference points for monitoring any potential recovery.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts may apply different periods. For KYNB, the most important near-term items are the next quarterly report (estimated around November 20, 2026), any FG-3246 Phase II data updates, changes to analyst targets, and the company's cash-burn and funding plans. I’m watching this closely as the clinical updates could shift the narrative quickly.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently. For investors following volatile small-cap biotech names like Kyntra Bio, automated signals can complement fundamental research.
Final Assessment
The question of whether KYNB can reach $37 — the average of five analyst targets spanning $30 to $43 — hinges almost entirely on clinical execution and sentiment rather than current fundamentals. At roughly $3.90, the move required is enormous, and the targets themselves largely predate the stock's recent decline. Support comes from a strong cash position, a focused oncology pipeline, and persistent Buy ratings; the principal obstacles are clinical risk, thin liquidity, and targets that may not yet reflect the new price reality. Investors should monitor clinical updates, analyst revisions, and cash runway rather than treat any single figure as a forecast.
Using Tickeron AI Tools in My Research
In my own work, I frequently rely on Tickeron’s AI Daily Buy/Sell Signals to help track momentum in names like this one. The platform’s AI-driven alerts provide an additional layer of insight alongside traditional analysis, especially when following micro-cap biotechs where sentiment can shift rapidly. It has become a useful part of my routine for spotting potential entry or exit points without replacing core fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KYNB in -15.08% downward trend, declining for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where KYNB declined for three days, in 293 of 339 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for KYNB entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where KYNB advanced for three days, in 231 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
KYNB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.501) is normal, around the industry mean (3.498). P/E Ratio (0.082) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.689) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. KYNB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYNB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement